ACMT Position Statement: Off-Label Prescribing during COVID-19 Pandemic
Open Access
- 4 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Medical Toxicology
- Vol. 16 (3), 342-345
- https://doi.org/10.1007/s13181-020-00784-6
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Treating COVID-19—Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During PandemicsJAMA, 2020
- Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infectionCMAJ : Canadian Medical Association Journal, 2020
- Improving the odds of drug development success through human genomics: modelling studyScientific Reports, 2019
- Overview of FDA’s Expanded Access Program for Investigational DrugsTherapeutic Innovation & Regulatory Science, 2017